Wegovy Helps Patients With Heart Failure Avoid Heart Attack, Stroke

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 23, 2024.

By Ernie Mundell HealthDay Reporter

FRIDAY, Aug. 23, 2024 -- Research has already proven that the blockbuster weight-loss drug Wegovy (semaglutide) can slash a person's odds for heart attacks and strokes, and now more data from the same trial suggests that's even true for very ill patients with heart failure.

The finding also helps clear up a concern around the use of Wegovy in these patients, added study lead author Dr. John Deanfield, of University College London (UCL).

“This is important, as there were concerns that semaglutide might be harmful for people with a type of heart failure known as reduced ejection fraction, where the heart pumps less blood around the body," he explained in a UCL news release.

"Our findings show that the benefit of semaglutide was similar, regardless of heart failure type," said Deanfield, who is a professor of cardiology at the university.

Last November, Deanfield and his colleagues first reported that overweight or obese heart patients age 45 or older had a 20% lower odds for heart attack or stroke if they received weekly Wegovy injections for an average of 34 months.

That trial was funded by Wegovy's maker, Novo Nordisk, and involved more than 17,600 patients recruited from centers worldwide.

The new analysis looked at a subset of close to 4,300 patients from the same trial. All of these patients were deemed by doctors to have heart failure -- a condition where the heart's pumping action is impaired -- at the start of the trial.

Use of Wegovy was linked with a 28% reduction in "major adverse cardiac events" such as heart attack or strokes in this very ill cohort of heart failure patients, Deanfield's group reported.

In total, 9.1% of patients who were taking Wegovy had a major cardiac event, compared to 12.3% of those who got "dummy" placebo injections.

In addition, heart failure patients taking Wegovy had a 24% reduction in deaths linked to heart disease and a 19% reduction in deaths from any cause, the study found.

All of this held true regardless of what type of heart failure the patient had.

Deanfield's team compared outcomes for patients who had a form of the disease with preserved ejection fraction (where the heart pumps normally but remains too stiff to fill up properly) and another form involving reduced ejection fraction.

Wegovy appeared to boost outcomes for patients regardless of the type of heart failure they had, the researchers found.

Just how does semaglutide (also marketed as the diabetes medicine Ozempic) boost the health of heart failure patients?

According to the study authors, the drug may help improve blood sugar levels and blood pressure while easing inflammation. It might also exert direct effects on the heart muscle and blood vessels.

The new findings support the notion that heart failure patients may want to consider using semaglutide on top of their existing meds, the British team said.

There were some limitations on the study: The larger trial wasn't focused on heart failure per se, so another trial that does focus on this type of patient is needed, Deanfield and his team believe.

Also, the patients in this trial were largely white and male, so a trial involving a more diverse population is also needed, they said.

The new findings were published Aug. 23 in The Lancet journal.

Sources

  • University College London, news release, Aug. 22, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-08-26 13:54

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords